Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency

Clinical Endocrinology

Volumn 72, Issue 3, 2010, Pages 297-304

  Bleicken, Benjamin ^a   Hahner, Stefanie ^b   Loeffler, Melanie ^b   Ventz, Manfred ^a   Decker, Oliver ^c   Allolio, Bruno ^b   Quinkler, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDROCORTISONE; HYDROCORTISONE;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; BODY SURFACE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCEPTION; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEX; SHORT FORM 36; WELLBEING;

ADDISON DISEASE; ADRENAL INSUFFICIENCY; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; HYDROCORTISONE; MIDDLE AGED; QUALITY OF LIFE;

EID: 76649098582     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03596.x     Document Type: Article

References (26)

1. Arlt, W. Allolio, B. (2003) Adrenal insufficiency. Lancet, 361, 1881 1893.
2. Hahner, S., Loeffler, M., Fassnacht, M. et al. (2007) Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. Journal of Clinical Endocrinology and Metabolism, 92, 3912 3922.
3. Mah, P.M., Jenkins, R.C., Rostami-Hodjegan, A. et al. (2004) Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology (Oxford), 61, 367 375.
4. Bleicken, B., Hahner, S., Loeffler, M. et al. (2008) Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. European Journal of Endocrinology, 159, 811 817.
5. Ware Jr., J.E. Sherbourne, C.D. (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473 483.
6. Nemeth, G. (2006) Health related quality of life outcome instruments. European Spine Journal, 15 (Suppl 1 S44 S51.
7. Garratt, A., Schmidt, L., Mackintosh, A. et al. (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ, 324, 1417.
8. Ellert, U. Bellach, B.M. (1999) The SF-36 in the Federal Health Survey - description of a current normal sample. Gesundheitswesen, 61 (Spec No S184 S190.
9. Brahler, E., Schumacher, J. Brahler, C. (2000) First all-Germany standardization of the brief form of the Gissen Complaints Questionnaire GBB-24. Psychotherapie, Psychosomatik, Medizinische Psychologie, 50, 14 21.
10. Zigmond, A.S. Snaith, R.P. (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361 370.
11. Hinz, A., Brahler, E., Schwarz, R. et al. (2005) How useful is the calculation of total scores for questionnaires concerning health related quality of life? Psychotherapie, Psychosomatik, Medizinische Psychologie, 55, 221 228.
12. Lovas, K., Loge, J.H. Husebye, E.S. (2002) Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology (Oxford), 56, 581 588.
13. Thomsen, A.F., Kvist, T.K., Andersen, P.K. et al. (2006) The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology, 31, 614 622.
14. Bergthorsdottir, R., Leonsson-Zachrisson, M., Oden, A. et al. (2006) Premature mortality in patients with Addison's disease: a population-based study. Journal of Clinical Endocrinology and Metabolism, 91, 4849 4853.
15. Tomlinson, J.W., Holden, N., Hills, R.K. et al. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425 431.
16. Wong, V., Yan, T., Donald, A. et al. (2004) Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clinical Endocrinology (Oxford), 61, 131 137.
17. Merza, Z., Rostami-Hodjegan, A., Memmott, A. et al. (2006) Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology (Oxford), 65, 45 50.
18. Laureti, S., Falorni, A. Santeusanio, F. (2003) Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. Journal of Endocrinological Investigation, 26, 1071 1075.
19. Bliesener, N., Steckelbroeck, S., Redel, L. et al. (2003) Dose distribution in hydrocortisone replacement therapy has a significant influence on urine free cortisol excretion. Experimental and Clinical Endocrinology and Diabetes, 111, 443 446.
20. Riedel, M., Wiese, A., Schurmeyer, T.H. et al. (1993) Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Experimental Clinical Endocrinology, 101, 106 111.
21. Groves, R.W., Toms, G.C., Houghton, B.J. et al. (1988) Corticosteroid replacement therapy: twice or thrice daily? Journal of the Royal Society of Medicine, 81, 514 516.
22. Peacey, S.R., Guo, C.Y., Robinson, A.M. et al. (1997) Glucocorticoid replacement therapy: are patients over treated and does it matter? Clinical Endocrinology (Oxford), 46, 255 261.
23. Howlett, T.A. (1997) An assessment of optimal hydrocortisone replacement therapy. Clinical Endocrinology (Oxford), 46, 263 268.
24. Arlt, W., Rosenthal, C., Hahner, S. et al. (2006) Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clinical Endocrinology (Oxford), 64, 384 389.
25. Newell-Price, J., Whiteman, M., Rostami-Hodjegan, A. et al. (2008) Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clinical Endocrinology (Oxford), 68, 130 135.
26. Buttgereit, F., Doering, G., Schaeffler, A. et al. (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet, 371, 205 214.